FDA Grants Mesoblast Clearance for Ryoncil Registrational Trial in DMD

Mesoblast Limited has received clearance from the U.S. Food and Drug Administration (FDA) to proceed directly to a registrational clinical trial for its drug, Ryoncil, to treat Duchenne Muscular Dystrophy (DMD). This regulatory milestone allows the company to skip early-phase trials, significantly accelerating the drug's potential path to market. The decision is supported by Ryoncil's established safety profile in pediatric patients, as it is already FDA-approved for treating acute graft-versus-host disease in children. The therapy targets approximately 15,000 children living with DMD in the United States, representing a substantial market opportunity for the biotech firm. Investors view this development as a major positive, as it reduces development timelines and costs while providing a clearer route to commercialization. Mesoblast shares are expected to react favorably to this accelerated regulatory pathway in both the U.S. and Australian markets.